Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2013

View Archived Issues

Nintedanib shows no activity against recurrent high-grade gliomas

Phase II trial planned after phase I study completed with selumetinib in children with gliomas

Bispecific hexavalent antibody shows promise for treating lupus

ImmunoCellular Therapeutics reports phase II data for ICT-107

Integral Molecular generates MAbs against the P2X3 ion channel

KaloBios Pharmaceuticals presents phase I results for KB-004

AGI-14100 significantly reduces tumor burden in IDH1-mutant mouse model

Swiss group discloses new MPC modulators

Convergence Pharmaceuticals prepares novel sodium channel blockers for pain

New potassium channel modulators patented by Autifony Therapeutics

Piramal Enterprises synthesizes new pyrimidine compounds

Korean researchers present new antibodies that bind to RANKL for bone disorders

Mallinckrodt completes clinical trials of MNK-155

Novel Trk-A inhibitors designed by Merck & Co.

SPX-106T lowers cholesterol and triglyceride levels and prevents weight gain in vivo

Canadian approval for Lemtrada

FDA advisory committee votes in favor of Oralair for grass pollen allergy

Stem cell candidate receives orphan drug designation in Japan

FDA advisory committee recommends approval of dapagliflozin

Celator's phase III study of CPX-351 for AML cleared to continue by DSMB

CDRD Ventures launches spin-off company Kairos Therapeutics

Dementia Consortium launched in the UK to advance drug development

FDA approves Complera for patients with HIV switching from a stable regimen

Endocyte begins phase I study of EC-1456 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...